Damora Therapeutics (DMRA) Short-term Investments (2021 - 2024)

Damora Therapeutics has reported Short-term Investments for 4 years, with the latest figure at $6.1 million in Q1 2024.

• For the quarter ending Q1 2024, Short-term Investments fell 78.42% year-over-year to $6.1 million; the trailing twelve-month figure through Mar 2024 stood at $6.1 million (down 78.42% YoY), and the FY2023 full-year result was $11.7 million, down 57.41% from the prior year.
• Short-term Investments for Q1 2024 stood at $6.1 million, down from $11.7 million in the prior quarter.
• The five-year high for Short-term Investments was $49.2 million in Q2 2022, with the low at $6.1 million in Q1 2024.
• Historically, Short-term Investments has averaged $31.1 million across 4 years, with a median of $33.2 million in 2021.
• Annual changes were most pronounced in 2022 — Short-term Investments jumped 48.39% — and 2024, when it plunged 78.42%.
• Damora Therapeutics' Short-term Investments stood at $37.6 million in 2021, then declined by 27.08% to $27.4 million in 2022, then slumped by 57.41% to $11.7 million in 2023, then sank by 47.97% to $6.1 million in 2024.
• The last three Short-term Investments figures came in at $6.1 million (Q1 2024), $11.7 million (Q4 2023), and $21.1 million (Q3 2023), per Business Quant data.